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This double-blind, randomized study evaluated the effect
of nifedipine on restenosis after coronary angioplasty.
Two hundred forty-one patients with dilation of 271
coronary sites were randomized at the time of hospital
discharge to receive nifedipine, 10 mg (123 patients), or
placebo (liS patients) four times daily for 6 months. No
patient was known to have coronary artery spasm. The
mean duration of therapy was 4.4 ± 2 (mean ± SD)
months for nifedipine and 4.3 ± 2 months for placebo.
A restudy angiogram was available in 100 patients (81%)
in the nifedipine group and 98 patients (83%) in the
placebo group.
A recurrent coronary stenosis was noted in 28% of
patients in the nifedipine group and in 29.5% of those
Percutaneous transluminal coronary angioplasty ( I) has gained
increased acceptance as a safe and effective therapy for
coronary artery disease. Long-term benefit of coronary an-
giopla sty has been limited in some patients, however, by
the recurrence of stenotic lesions (2,3). Various adjunctive
therapies such as aspirin and other antiplatelet agents have
been propo sed to decrease such recurrences (4,5) .
Coronary artery spasm has been observed after angio-
plasty (6-8) and subclinical spasm was thought to be causally
related to restenosi s (6,8) . Spasm usually occurs during the
first 2 months after angioplasty (6) and most restenose s are
identified between 2 and 6 months (2, 9) . The effectiveness
of nifedipine in the treatment of coronary artery spasm (10-12)
has encouraged the routine use of nifedipine and other cal-
cium blocking drugs in the months after coronary angio-
plasty . This practice has been maintained although there has
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in the placebo group (p = NS). The mean diameter
stenosis was 36.4 ± 23% for the nifedipine group and
36.7 ± 23% for the placebo group (p = NS). By pill
count, 78% of patients receiving nifedipine and 82% of
those receiving placebo complied with the study drug
regimen. Coronary stenosis recurred in 33% of patients
in the placebo group and in 29% of patients in the ni-
fedipine group who complied with the regimen and had
angiograms (p = NS). In conclusion, the study did not
demonstrate a significant beneficial effect of nifedipine
on the incidence of recurrent stenosis after successful
percutaneous transluminal coronary angioplasty.
(J Am Coli CardioI1986;8:1271-6)
been little evidence that such treatment is of benefit in re-
ducing lesion recurrence . Our study was undertaken to pro-
spectively evaluate the effectiveness of nifedipine in pre-
venting restenosis in patient s after successful coronary
angioplasty.
Methods
Study patients. Between July 23, 1982 and December
7, 1983, coronary angioplasty was attempted at 1,932 vessel
sites in 1,710 patients. All patients had characteristic symp-
toms or objective clinical evidence of myocardial ischemia
based on spontaneous electrocardiographic T wave changes
or stress testing data. The angioplasty procedure was per-
formed by the femoral route using a standard technique
described elsewhere (13,14). Successful dilation (20% re-
duction in stenosis diameter) was achieved in 1,748 lesions
(90.5%). Patients aged 21 to 75 years without reocclusion
within 48 hours were considered candidates for the study .
Patients were excluded if they had a history of adverse
response to any calcium antagonist, documented coronary
artery spasm or incomplete revascularization necessitating
antianginal medication using a calcium antagonist. Two
0735-1097/86/$3.50
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Table 1. Baseline Characteristics of 241 Patients
*Values are means ± SO. LAD = left anterior descending coronary
artery; LCx = left circumflex coronary artery; RCA = right coronary
artery.
Results
Baseline characteristics (Tables 1 and 2). The nifed-
ipine and placebo treatment groups were comparable in age,
sex, previous angina history and history of myocardial in-
farction (Table I). Twenty more right coronary artery le-
sions were dilated in the nifedipine group and 15 more left
Nifedipine Placebo p Value
Patients (n) 123 118
Age (yr)* 53 ± 9 55 ± 10 NS
Sex: male 106 (86%) 103 (87%) NS
Previous myocardial 32 (26%) 24 (20%) NS
infarction
Duration of angina 11 ± 21 8 ± 16 NS
(mo)*
Vessel dilated (n)
LAD 67 (49%) 82 (61%) NS
LCx 21 (16%) 25 (18%) NS
RCA 48 (35%) 28 (21%) <0.05
Total 136 135
Lesion length (mm)* 6.5 ± 4 6.4 ± 4 NS
Eccentric lesion 48 (36%) 60 (44%) NS
<0.05
NS
<0.05
NS
p Value
69 ± 14
23 ± 10
52 ± 14
12 ± 7
Placebo
(n = 118)
48 ± 13
II ± 6
73 ± 13
23 ± 11
Nifedipine
(n = 123)
Diameter stenosis (%)
Before PTCA
After PTCA
Pressure gradient (mm Hg)
Before PTCA
After PTCA
PTCA = percutaneous transluminal coronary angioplasty.
least two projections using a computerized caliper system.
Diameter stenosis was calculated as the mean of measure-
ments in two or three available projections.
Statistical analysis. Data from the 241 patients were
analyzed by intention to treat as well as by groups judged
compliant with the study drug regimen. Recurrence rates
were determined by the total number of lesions dilated (271
lesions) as well as by the total number of patients (241
patients). Patients with dilation of multiple sites were con-
sidered to have recurrence if anyone site dilated had a
recurrence. Comparison of discrete variables was done using
a chi-square analysis. Continuous variables were compared
using an unpaired or paired Student's t test as appropriate.
A probability (p) value of less than 0.05 was considered
significant.
Table 2. Angioplasty Results in 241 Patients
hundred forty-one patients with 271 dilated coronary lesions
agreed to participate in the study. The study was approved
by the Ethics Committee of this institution and all patients
gave written informed consent.
Study design. The study was performed double-blind
with patients randomized at 48 hours after angioplasty to
either 10 mg of nifedipine or placebo four times daily.
Immediately before arterial dilation, patients received 10
mg of nifedipine and 0.4 mg of nitroglycerin sublingually,
and 200 /Lg of intracoronary nitroglycerin. All patients re-
ceived calcium antagonist treatment for 48 hours after the
procedure. The study drugs were provided for 6 months by
the manufacturer as uniform capsules in numbered lots.
These were grouped by a computer-generated random code
in blocks of 10. All patients except three (two taking ni-
fedipine, one taking the placebo) received 325 mg aspirin
daily. Other medications prescribed during the follow-up
period were determined by primary physicians.
Follow-up protocol. Patients were given a 2 month sup-
ply of the study drug at hospital discharge. The remaining
4 month supply was provided after compliance was checked
at 1 month. All patients were questioned before angioplasty
regarding the nature, frequency and duration of their chest
pain. Questionnaires regarding angina, work status and ac-
tivity level were sent to patients after 3 and 6 months of
therapy. Recurrence of chest pain similar to that experienced
before arterial dilation was considered positive evidence of
restenosis regardless of the severity, duration or frequency
of pain. These data were obtained from written question-
naires sent to all patients. ,
Compliance with the study drug regimen was evaluated
by a count of unused capsules returned after 1 and 6 months
of therapy. Patients were judged compliant who took at least
75% of their medication until either 6 months of therapy
was completed or symptoms suggesting recurrent stenosis
developed and early discontinuation of the study drug was
required.
All patients and referring physicians were contacted to
arrange a restudy angiogram after completion of therapy.
Letters at 6 months, follow-up telephone calls and repeat
mailings were utilized. Follow-up angiograms performed
elsewhere were forwarded to our institution for analysis.
When follow-up arteriography was not available, exercise
test results were forwarded to our institution. A positive
follow-up exercise test was defined as a reversible scinti-
graphic defect (thallium) in the vascular distribution of the
dilated artery or 1 mm of horizontal or downsloping ST
segment depression of 80 ms or more past the J point in the
electrocardiogram.
Restenosis. Restenosis was defined as the loss of at least
50% of the gain in luminal diameter accomplished at initial
dilation. An additional analysis of restenosis in each group
defined restenosis as a lesion of 50% or greater in diameter
on the restudy angiogram. Stenoses were measured in at
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Table 3. Incidence of Recurrence of Coronary Stenosis
Restenosis (Table 3). A restudy coronary angiogram
was available in 100 (81%) of the 123 patients taking ni-
fedipine at 6.5 ± 2 months after coronary angioplasty and
in 98 (83%) of the 118 patients taking placebo at 6.6 ± 3
months after angioplasty. A recurrent stenosis was noted in
at least one of the dilated sites in 28 (28%) of the 100 patients
receiving nifedipine and 29 (29.5%) of the 98 patients re-
ceiving placebo for whom an angiogram was available. With
the inclusion of exercise test data, objective information
was available for III (90%) of 123 patients receiving ni-
fedipine and 110 (93%) of 118 of those receiving placebo.
Including all such objective data, the recurrence rate was
27.0% (30 of 111) in the nifedipine group and 27.3% (30
of 110) in the placebo group (Table 3A).
Restenosis was also defined and analyzed as a lesion
50% or greater in diameter, which may sometimes better
reflect hemodynamic significance. The frequency of recur-
rence remained similar between the two groups with 26
patients receiving placebo and 27 patients receiving nifed-
ipine having at least one lesion noted on restudy arteriog-
raphy.
Multiple sites were dilated in 29 (14%) of the 241 pa-
tients, totaling 271 lesions. Distribution of these patients
was similar in both treatment groups (Fig. I). The incidence
of recurrent stenosis per lesion, including only those with
objective follow-up, was 26% (32 of 124) of the nifedipine
group and 27% (34 of 124) of the placebo group (p = NS).
The mean diameter stenosis for all lesions with follow-up
angiograms was 36.4 ± 23% in the nifedipine group and
36.7 ± 23% (p = NS) in the placebo group. The distri-
bution of the values obtained on the restudy angiogram also
did not differ significantly.
When only those patients judged compliant with therapy
were analyzed, there remained no significant difference in
restenosis (Table 3B). A recurrent stenosis was identified
by objective data in 27% (25 of 92) of patients in the ni-
fedipine group and 31% (29 of 92) of those in the placebo
group (p = NS). When individual vessel sites were ana-
lyzed, 25% (26 of 103) of sites in the nifedipine group and
32% (33 of 103) of sites in the placebo group showed re-
anterior descending artery lesions in the placebo group (Ta-
ble I). The extent of disease was comparable in both groups,
with a higher percent diameter stenosis in the nifedipine
group but a higher transstenotic pressure gradient in the
placebo group (Table 2). Results of dilation were similar in
both groups as measured by percent diameter stenosis and
transstenotic pressure gradient. The procedure resulted in a
mean decrease in diameter stenosis of 50% in the nifedipine
group and 46% in the placebo group. Of the 136 lesions in
the nifedipine group, the immediate postdilation residual
diameter was 30% or less in 111 patients, 31 to 40% in 20
patients, 41 to 50% in 3 patients and greater than 50% in
only 2 patients. Of the 135 lesions in the placebo group the
residual diameter was 30% or less in 104 patients, 31 to
40% in 23 patients and 41 to 50% in 8 patients. The inci-
dence of intimal tears was also similar, occurring in 22%
of patients receiving nifedipine and 21% of those receiving
placebo. Multivariate, stepwise regression analysis of base-
line factors showed that lesions in the left anterior descend-
ing and right coronary arteries were associated with a higher
rate of restenosis (p = 0.02). In addition, patients with a
shorter duration of angina tended to have a higher rate of
restenosis (p = 0.09).
Compliance and duration of therapy. Compliance with
the study drug regimen was similar in both groups. Ninety-
six patients (78%) in the nifedipine group and 97 (82%) of
the placebo group took at least 75% of the prescribed dose
of the study drug. Therapy was continued in these patients
for 6 months or until symptoms suggesting ischemia re-
quired early discontinuation of therapy. Noncompliance was
due to side effects in 22 patients receiving nifedipine and
11 patients receiving placebo (p < 0.1). Other causes of
noncompliance were the patient's desire to leave the study
or lack of 75% compliance with drug dosage (five patients
taking nifedipine, 10 patients taking the placebo, p = NS).
The mean duration of therapy with the study drug in the
overall nifedipine and placebo groups was not statistically
different (4.4 ± 2 and 4.3 ± 2 months, respectively).
Therapy was terminated before 6 months in 41% of the total
nifedipine group and 43% of the total placebo group. Among
compliant patients, 25% assigned to nifedipine and 32%
assigned to placebo discontinued the drug before 6 months.
The mean duration of therapy for these patients tended to
be longer in the nifedipine group (5.3 ± 1 months) than in
the placebo group (4.9 ± 2 months) (p < 0.1). Although
the total number of patients who stopped the study drug in
the first 2 months was similar for the two groups (35 taking
nifedipine, 38 taking placebo, p = NS), during this period,
patients in the placebo group were more likely than those
in the nifedipine group to discontinue the regimen because
of chest pain (18 versus 8 patients, p < 0.1). Patients taking
nifedipine were more likely to discontinue the drug during
these initial 2 months because of side effects (27 patients)
than because of chest pain.
Angiography
Exercise stress test
Total
Angiography
Exercise stress test
Total
*p = NS.
Nifedipine
A. All Patients
28/100 (28%)
2/11 (18%)
30/111 (27%)*
B. Compliant Patients
24/84 (29%)
1/8 (12%)
25/92 (27%)*
Placebo
29/98 (29.5%)
IJl2 (8%)
301110 (27%)*
28/84 (33%)
118 (12%)
29/92 (31.5%)*
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Figure 1. Frequency distribution of 220 patients in
different coronary diameterstenosisgroupsat the time
of the restudy angiogram. Values under each bar de-
note the number of patients.
*Number of patients in whom the drug was discon-
tinued is given in parentheses. tp < 0.05.
currence (p = NS). The mean diameter stenosis was 36 ±
22% for the nifedipine group and 38 ± 24% for the placebo
group (p = NS).
Chest pain was reported by 52 (42%) of 123 patients in
the nifedipine group and 55 (47%) of 118 patients in the
placebo group (p = NS). Among patients who complied
with therapy, complaints of chest pain were similar: 46%
(44 of 96) for the nifedipine group and 49% (47 of 97) for
the placebo group. Chest pain, however, was unreliable in
predicting restenosis. Among patients for whom both an-
giographic follow-up and chest pain data were available,
only 40% (19 of 47) of those in the nifedipine group and
49% (23 of 47) of those in the placebo group complaining
of chest pain were found to have recurrence. Among patients
Table 4. Side Effects in 241 Patients
Peripheral edema
Dizziness
Mood change
Nausea
Palpitation
Hypertension
Headache
Weakness
Muscle cramps
Nocturia
Hiccup
Total
Nifedipine*
(n = 123)
12 (9)
5 (4)
5 (4)
3 (3)
I (I)
I
o
o
o
1 (1)
o
28 (22)
Placebo*
(n = 118)
2 (I)
o
o
5 (5)
o
I (I)
I (I)
I (I)
1 (I)
o
I (I)
12 (l1)t
who did not report chest pain, 14.6% (7 of 48) of those
receiving nifedipine and 12.5% (6 of 48) of those receiving
placebo had recurrent stenoses.
Side effects with the study drug (Table 4). These were
more common in the nifedipine than in the placebo group.
Twenty-three percent of the former (28 of 123) and 10%
(12 of 118) of the latter reported adverse reactions. Side
effects severe enough to require discontinuation of the study
drug also tended to be greater in the nifedipine group. The
most common complaints by patients treated with nifedipine
were peripheral edema, dizziness and mood changes; nausea
was most often cited in the placebo group.
Discussion
Previous reports (6,7,8,15) have noted a higher rate of
recurrent coronary stenosis in patients with coronary artery
spasm after successful coronary angioplasty. It has been
suggested that unrecognized coronary spasm in many pa-
tients after angioplasty may contribute to restenosis at the
dilated site. Accordingly, large numbers of patients were
and are still receiving calcium blocking drugs as routine
discharge medication. This study demonstrated no signifi-
cant effect of nifedipine therapy on either mean residual
coronary stenosis on follow-up angiography or incidence of
patients with recurrent stenoses. This finding pertained when
both the total group and only patients with proved compli-
ance with the study drug regimen were analyzed.
Influence of baseline characteristics on restenosis. Al-
though there were some minor differences in the baseline
characteristics of the two randomized groups, these do not
appear to have affected the results. The mean percent ste-
nosis before angioplasty was higher in the nifedipine group;
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however, this is balanced by the mean pressure gradient
before angioplasty, which was higher in the placebo group.
In the subset of patients judged compliant with therapy, the
duration of angina in the placebo group was significantly
shorter (p < 0.05). This has been associated with an in-
creased recurrence rate and would tend to favor restenosis
in the placebo group. Other factors identified with an in-
creased recurrence rate were similar in both study groups.
These include male sex (2), no previous myocardial infarc-
tion (2), increased final coronary pressure gradient (2,16)
and absence of intimal tear (16);
Comparison with previous studies. Other centers have
also evaluated the effect of calcium antagonist treatment
after angioplasty. Our results concur with the laboratory
findings of Faxon et al. (17). They demonstrated a com-
parable recurrence of stenosis for control versus nifedipine
treatment in atherosclerotic rabbits 4 weeks after experi-
mental angioplasty. In a preliminary report Val et al. (15)
compared sulfinpyrazone and diltiazem with sulfinpyrazone
treatment alone after successful coronary angioplasty. They
found no improved clinical or angiographic outcome in pa-
tients treated with diltiazem. Recently in a smaller, pro-
spective, although nonblinded trial, Corcos et al. (18) re-
ported no decrease in the incidence of recurrent stenosis
with the addition of diltiazem to platelet inhibitor therapy.
Stenosis recurred in only 7 of 50 coronary segments dilated
in the diltiazem group and 10 of 53 segments in the control
group. They required a restudy stenosis of 70% or greater
to define a recurrent stenosis, which would appear to explain
their lower incidence of restenosis.
Chestpain after angioplasty. There was no significant
difference in the incidence of chest pain between the nifed-
ipine and placebo groups. In addition, the unreliability of
chest pain history as a predictor of recurrent stenosis was
the same in both groups. Among our patients reporting chest
pain, this finding was unreliable in predicting a recurrent
stenosis, and in other patients the absence of chest pain was
unreliable in predicting continued success. These findings
concur with those of the National Heart, Lung, and Blood
Institute Coronary Angioplasty Registry (2). However, there
was a greater tendency for the onset of chest pain to occur
during the first 2 months after angioplasty in the placebo
group. It is possible that the antianginal effect of nifedipine
delayed the recurrence of symptoms although not the in-
cidence of lesion restenosis.
Clinical implications. We were unable to identify a
beneficial effect of nifedipine in decreasing the incidence
or degree of restenosis after coronary angioplasty. This im-
plies that coronary artery spasm does not playa significant
role in the pathogenesis of such restenosis after angioplasty
in the general patient population. Our patient group did not
include those with clinically apparent coronary artery spasm,
however, and previous reports (6-8,19,20) have identified
a high incidence of restenosis in these patients. Patients
should be screened closely for evidence of coronary artery
spasm and such patients treated with aggressive medical
therapy. In patients without coronary artery spasm, we can
no longer justify calcium antagonist therapy on a routine
basis after coronary angioplasty.
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